Chapman R S, Whetton A D, Dive C
Department of Biochemistry, University of Manchester Institute of Science and Technology, United Kingdom.
Cancer Res. 1994 Oct 1;54(19):5131-7.
Cells with a temperature-sensitive mutant of the v-abl oncoprotein (IC.DP) were treated with the anticancer drugs melphalan or hydroxyurea. At the restrictive temperature for v-ABL protein tyrosine kinase activity, drug-treated IC.DP cells died by apoptosis. In contrast, apoptotic cell death induced by either drug was suppressed when v-ABL was active. However, melphalan-induced accumulation of cells in the S and G2-M phases of the cell cycle was unaffected by v-ABL activation. Moreover, the continuous presence of v-ABL activity was necessary to suppress apoptosis. This suggested that melphalan had interacted with DNA and that v-ABL activity prevented the coupling of drug-induced damage to the apoptotic pathway. IC.DP cells exhibited similar levels and subcellular localization of the BCL-2 protein irrespective of v-ABL activation status, thus v-ABL-mediated cell survival appeared to be independent of BCL-2.
用抗癌药物美法仑或羟基脲处理带有v-abl癌蛋白温度敏感突变体(IC.DP)的细胞。在v-ABL蛋白酪氨酸激酶活性的限制温度下,经药物处理的IC.DP细胞通过凋亡死亡。相反,当v-ABL有活性时,两种药物诱导的凋亡细胞死亡均受到抑制。然而,美法仑诱导的细胞在细胞周期S期和G2-M期的积累不受v-ABL激活的影响。此外,持续存在v-ABL活性对于抑制凋亡是必要的。这表明美法仑与DNA发生了相互作用,并且v-ABL活性阻止了药物诱导的损伤与凋亡途径的耦联。无论v-ABL的激活状态如何,IC.DP细胞均表现出相似水平和亚细胞定位的BCL-2蛋白,因此v-ABL介导的细胞存活似乎独立于BCL-2。